Susvimo® (ranibizumab injection) has become the first FDA-approved continuous delivery system for diabetic retinopathy (DR), reducing treatment frequency to once every nine months.1 The approval is based on the positive results of the phase III Pavilion study, showing significant improvement in disease severity.

The FDA has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME). Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME while requiring fewer treatments than standard-of-care eye injections.

4D Molecular Therapeutics, a clinical-stage genetic medicines company, has announced promising topline interim results from Part 1 of the SPECTRA clinical trial evaluating 4D-150, a novel treatment for diabetic macular edema (DME).

The EURETINA 2024 Congress, held in Barcelona from September 19-22, brought together leading experts in ophthalmology to share the latest research and innovative treatments for retinal diseases. Among the highlights were several late-breaking abstracts that showcased promising advances in therapeutics for conditions such as retinopathy of prematurity (ROP), diabetic retinopathy (DR) and  age-related macular degeneration (AMD). These studies not only demonstrated the efficacy and safety of novel treatment options but also addressed critical unmet needs in reducing patient burden and improving long-term outcomes.

Neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME) are two leading causes of visual impairment and blindness in the USA.1,2 Faricimab is the first bispecific antibody approved by the US Food and Drug Administration in ophthalmology and was ...

Retinal pharmacotherapy encompasses various drug delivery routes that offer potential avenues for effective treatment (Figure 1). Among these, intravitreal injections have emerged as the predominant method employed in clinical practice.1 They have established themselves as the primary approach for administering anti-vascular ...

The term ‘artificial intelligence’ was coined by a group of scientists during a workshop known as the “Dartmouth Summer Research Project on Artificial Intelligence” in 1956.1 The concept was based on the idea that “intelligent human behavior consisted in processes that ...

Faricimab inhibits both angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways which may extend treatment durability beyond current anti-VEGF therapies for diabetic macular edema (DME). It was a pleasure to speak with Dr Jennifer Lim (University of Illinois ...

Diabetic macular edema is characterised by exudative fluid accumulation in the macula and is the most common form of sight-threatening retinopathy in people with diabetes affecting one in 15 people with diabetes. Intraocular pharmacotherapy with anti-VEGF agents is the standard of ...